Brief: Amylyx Pharmaceuticals Announces Acquisition Of Phase 3-Ready GLP-1 Receptor Antagonist (Avexitide) With FDA Breakthrough Therapy Designation
10/07/2024 12:13
July 10 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O :
* AMYLYX PHARMACEUTICALS ANNOUNCES ACQUISITION OF PHASE
3-READY
GLP-1 RECEPTOR ANTAGONIST (AVEXITIDE) WITH FDA BREAKTHROUGH
THERAPY DESIGNATION
* AMYLYX PHARMACEUTICALS INC - AVEXITIDE TO ENTER PHASE 3
TRIALS
IN Q1 2025
* AMYLYX PHARMACEUTICALS: ENGAGING IN TALKS WITH BROADER
CONGENITAL HI COMMUNITY TO DEVELOP PATH FORWARD BASED ON
PROMISING PHASE 2 STUDY RESULTS
Source text for Eikon: ID:nBw5swNPja
Further company coverage: AMLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock